# GH Research Reports Full Year 2025 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/GHRS/gh-research-reports-full-year-2025-financial-results-and-provides-business-update
Ticker: GHRS
Company: GH Research
Source: GH Research
Published: 2026-03-05 12:00 EST
Original Source URL: https://investor.ghres.com
## Summary

Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Cash, cash equivalents and marketable securities of $280.7 million as of December 31, 2025 DUBLIN,

## Article Body
Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Cash, cash equivalents and marketable securities of $280.7 million as of December 31, 2025 DUBLIN,
## Recent Company News
- 2026-06-04 11:00 EST — [GH Research Announces Publication of Phase 2a Postpartum Depression Results](https://biopharmsignal.com/news/GHRS/gh-research-announces-publication-of-phase-2a-postpartum-depression-results) — Source: GH Research
- 2026-05-14 11:00 EST — [GH Research Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/GHRS/gh-research-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: GH Research
- 2026-04-29 12:00 EST — [GH Research Announces Pricing of $117.5 Million Underwritten Offering](https://biopharmsignal.com/news/GHRS/gh-research-announces-pricing-of-117-5-million-underwritten-offering) — Source: GH Research
- 2026-04-20 13:00 EST — [GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness](https://biopharmsignal.com/news/GHRS/gh-research-welcomes-white-house-executive-order-to-accelerate-medical-treatments-for-serious-mental-illness) — Source: GH Research
- 2026-03-25 15:11 EST — [GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD](https://biopharmsignal.com/news/GHRS/gh-research-announces-publication-of-phase-2b-results-for-mebufotenin-gh001-in-jama-psychiatry-and-reports-new-finding-of-severity-independent-efficacy-in-trd) — Source: GH Research
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)